This trial is looking at the safety, tolerability and effectiveness of a medication named cobisitat in HIV postitive individuals. Both naïve (never been on therapy) and treatment experienced patients are being considered. This trial will be looking at the effectiveness of the combination of Darunavir with cobisistat with an investigator defined backbone. The duration of this trial is at least 48 weeks or approximately one year.
Who may be Eligible
Any HIV positive patient may be considered for the study. Treatment-experienced patients must have an undectable viral load for at least 6 months prior to screening